New Biomarker Screening for Protective Immunity in Sars-Cov-2 Vaccinees

"Background: A heterologous prime-boost COVID vaccination using different vaccine platforms has been deployed to facilitate vaccination program scale-up. In the initial phase of this project, we attempted to identify early biomarkers from the plasma. However, in the preliminary findings, we observed a relatively weak correlation between the cytokine levels in the early plasma of the vaccines and the antibody response post booster administration.
Nevertheless, we noted a significant correlation between the pre-existing antibody levels and CD4+ T cell immune response with the antibody response post booster administration. Therefore, in this study, we aim to evaluate the immune response of T cells, the concentration of IgG and neutralizing antibodies in the blood of vaccine recipients. This assessment is conducted to rapidly determine whether the recipients have acquired sufficient protection against the novel coronavirus. Additionally, we plan to assess the feasibility of developing rapid test strips based on the relevant cytokines, aiming to improve the accessibility and immediacy of the detection process."